DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

Phase 2

Not yet recruiting

Conditions: CLL/SLL

Interventions: Drug: Orelabrutinib and BG

First Posted Date: 2023-06-26

Last Posted Date: 2023-06-26

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 24

Registration Number: NCT05918276

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
The Central Hospital Of Wuan, Wuhan, Hubei, China

Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction

Not yet recruiting

Conditions: Stroke

Interventions: Drug: Osmotic drugs

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-22

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 2592

Registration Number: NCT05914272

Locations: 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳
Hainan Traditional Chinese Medicine Hospital, Haikou, Hainan, China
🇨🇳
The First Hospital of Changsha, Changsha, Hunan, China

and more 16 locations

Optical Biopsy for Peritoneal Nodules in Colorectal Patients

Not Applicable

Recruiting

Conditions: Colorectal Cancer

Interventions: Diagnostic Test: Confocal laser endomicroscopy

First Posted Date: 2023-05-30

Last Posted Date: 2023-08-23

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 278

Registration Number: NCT05879783

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

Not Applicable

Recruiting

Conditions: Locally Advanced
MSS
Rectal Cancer
High-Risk

Interventions: Drug: Toripalimab
Radiation: short-term radiotherapy
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-05-26

Last Posted Date: 2023-07-05

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 53

Registration Number: NCT05877573

Locations: 🇨🇳
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China

A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure

Not yet recruiting

Conditions: AML

Interventions: Combination Product: CLAG

First Posted Date: 2023-05-25

Last Posted Date: 2023-07-05

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 137

Registration Number: NCT05875649

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guangdong, China

Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy

Not yet recruiting

Conditions: Acute Ischemic Stroke

First Posted Date: 2023-05-06

Last Posted Date: 2023-05-06

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 2592

Registration Number: NCT05845372

Locations: 🇨🇳
Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China

and more 16 locations

Adjunctive Esketamine for Analgesia in Mechanically Ventilated Septic Shock Patients

Phase 3

Recruiting

Conditions: Septic Shock
Mechanical Ventilation Complication

Interventions: Drug: Saline
Drug: Esketamine
Drug: Remifentanil + propofol
Procedure: Pain and Sedation Assessment

First Posted Date: 2023-05-03

Last Posted Date: 2023-11-22

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 124

Registration Number: NCT05839366

Locations: 🇨🇳
Southern medical university Nanfang hospital, Guangzhou, China

Evaluation of the Effect of HFMT in Promoting Donor-site Wound Healing

Not Applicable

Completed

Conditions: Wound Heal

Interventions: Other: Mupirocin ointment
Other: HFMT cell suspension

First Posted Date: 2023-05-03

Last Posted Date: 2023-07-03

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 100

Registration Number: NCT05839158

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer

Not Applicable

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: FOLFOX , FOLFIRI or FOLFOXIRI regimens
Drug: FOLFOX or CapeOX regimens

First Posted Date: 2023-04-27

Last Posted Date: 2023-06-28

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 186

Registration Number: NCT05832398

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

Phase 2

Recruiting

Conditions: Chemotherapy
Immunotherapy

Interventions: Drug: Camrelizumab

First Posted Date: 2023-04-24

Last Posted Date: 2023-04-25

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 57

Registration Number: NCT05825443

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guandong, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy